Proleukin - Medical Health Care Library Wiki


Main Article	Forum

Proleukin

	Original Author Healthocrates Staff
	Physician/Scientist L. Hudson Lori
	Health Care Professional No contributions yet. Be the first!
	Contributing Member No contributions yet. Be the first!
	Add New Topic Tab

Brand Name:	Proleukin	Trade Name:	Aldesleukin

FDA Approved For:	Adults with metastatic renal cell carcinoma (metastatic RCC). PROLEUKIN is indicated for the treatment of adults with metastatic melanoma.	Pediatric Use:

Carcinogen:		Mutagen:

Manufacturer and/or Distributor:	Chiron Corp

Adverse Reactions:

The rate of drug-related deaths in the 255 metastatic RCC patients who received single-agent PROLEUKIN (aldesleukin) was 4% (11/255); the rate of drug-related deaths in the 270 metastatic melanoma patients who received single-agent PROLEUKIN was 2% (6/270)... The following life-threatening (grade 4) events were reported by <1% of the 525 patients: hypothermia; shock; bradycardia; ventricular extrasystoles; myocardial ischemia; syncope; hemorrhage; atrial arrhythmia; phlebitis; AV block second degree; endocarditis; pericardial effusion; peripheral gangrene; thrombosis; coronary artery disorder; stomatitis; nausea and vomiting; liver function tests abnormal; gastrointestinal hemorrhage; hematemesis; bloody diarrhea; gastrointestinal disorder; intestinal perforation; pancreatitis; anemia; leukopenia; leukocytosis; hypocalcemia; alkaline phosphatase increase; BUN increase; hyperuricemia; NPN increase; respiratory acidosis; somnolence;

Notes:

[Watch page ]

EditText of this page (last edited August 23, 2008)